Which outcome is associated with C1q deficiency?

C1q deficiency is closely associated with the development of systemic lupus erythematosus (SLE), an autoimmune condition. C1q is an essential component of the complement system, which plays a critical role in the immune response. When C1q is deficient, the body has impaired clearance of apoptotic cells and immune complexes, leading to increased immune activation and the potential for the development of autoimmune conditions like SLE.

Patients with C1q deficiency tend to have a higher prevalence of various autoimmune phenomena, particularly SLE, which aligns with the characteristic symptoms and complications associated with this disorder. This is why the link between C1q deficiency and SLE is well established in the literature.

In contrast, while increased risk of infections might occur in other complement deficiencies, C1q deficiency is more specifically tied to autoimmune conditions. Similarly, asthma and impaired blood clotting are not direct outcomes or associations of C1q deficiency.